Abstract
Objective:
The aim of this study was to investigate the effect of maternal magnesium sulfate (MgSO4) exposure for eclampsia prophylaxis on neonatal intensive care unit (NICU) admission rates for term newborns.
Study Design:
A secondary analysis of the Maternal–Fetal Medicine Unit Network Cesarean Registry, including primary and repeat cesarean deliveries, and failed and successful trials of labor after cesarean was conducted. Singleton pregnancies among women with preeclampsia and >37 weeks of gestation were included. Pregnancies with uterine rupture, chorioamnionitis and congenital malformations were excluded. Logistic regression analysis was used to determine associations between MgSO4 exposure and NICU admission. P<0.05 was considered statistically significant.
Result:
Two thousand one hundred and sixty-six term pregnancies of women with preeclampsia were included, of whom 1747 (81%) received MgSO4 for eclampsia prophylaxis and 419 (19%) did not. NICU admission rates were higher among newborns exposed to MgSO4 vs unexposed (22% vs 12%, P<0.001). After controlling for neonatal birth weight, gestational age and maternal demographic and obstetric factors, NICU admission remained significantly associated with antenatal MgSO4 exposure (adjusted odds ratio 1.9, 95% confidence interval 1.3 to 2.6, P<0.001). Newborns exposed to MgSO4 were more likely to have Apgar scores <7 at 1 and 5 min (15% vs 11% unexposed, P=0.01 and 3% vs 0.7% unexposed, P=0.008). There were no significant differences in NICU length of stay (median 5 (range 2 to 91) vs 6 (3 to 15), P=0.5).
Conclusion:
Antenatal maternal MgSO4 treatment was associated with increased NICU admission rates among exposed term newborns of mothers with preeclampsia. This study highlights the need for studies of maternal MgSO4 administration protocols that optimize maternal and fetal benefits and minimize risks.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Lucas MJ, Leveno KJ, Cunningham FG . A comparison of magnesium sulfate with phenytoin for the prevention of eclampsia. N Engl J Med 1995; 333: 201–205.
Altman D, Carroli G, Duley L, Farrell B, Moodley J, Neilson J et al. Do women with pre-eclampsia, and their babies, benefit from magnesium sulphate? The MAGPIE trial: a randomised placebo-controlled trial. Lancet 2002; 359: 1877–1890.
Duley L, Gulmezoglu AM, Henderson-Smart DJ, Chou D . Magnesium sulphate and other anticonvulsants for women with pre-eclampsia. Cochrane Database Syst Rev 2010; 11: CD000025.
Norwitz ER, Bahtiyar MO, Sibai BM . Defining standards of care in maternal-fetal medicine. Am J Obstet Gynecol 2004; 191: 1491–1496.
Lewis DF . Magnesium sulfate: the first-line tocolytic. Obstet Gynecol Clin North Am 2005; 32: 485–500.
Rouse DJ, Hirtz DG, Thom E, Varner VW, Spong CY, Mercer BM et al. A randomized, controlled trial of magnesium sulfate for the prevention of cerebral palsy. N Engl J Med 2008; 359: 895–905.
Crowther CA, Hiller JE, Doyle LW, Haslam RR, Australasian Collaborative Trial of Magnesium Sulphate (ACTOMg SO4) Collaborative Group. Effect of magnesium sulfate given for neuroprotection before preterm birth: a randomized controlled trial. JAMA 2003; 290: 2669–2676.
Costantine MM, Weiner SJ, Eunice Kennedy Shriver National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. Effects of antenatal exposure to magnesium sulfate on neuroprotection and mortality in preterm infants: a meta-analysis. Obstet Gynecol 2009; 114: 354–364.
Lipsitz PJ, English IC . Hypermagnesemia in the newborn infant. Pediatrics 1967; 40: 856–862.
Lipsitz PJ . The clinical and biochemical effects of excess magnesium in the newborn. Pediatrics 1971; 47: 501–509.
Rasch DK, Huber PA, Richardson CJ, L'Hommedieu CS, Nelson TE, Reddi R . Neurobehavioral effects of neonatal hypermagnesemia. J Pediatr 1982; 100: 272–276.
Belfort MA, Anthony J, Saade GR, Allen JC Jr, Nimodipine Study Group. A comparison of magnesium sulfate and nimodipine for the prevention of eclampsia. N Engl J Med 2003; 348: 304–311.
Lyell DJ, Pullen K, Campbell L, Ching S, Druzin ML, Chitkara U et al. Magnesium sulfate compared with nifedipine for acute tocolysis of preterm labor: a randomized controlled trial. Obstet Gynecol 2007; 110: 61–67.
Greenberg MB, Penn AA, Thomas LJ, El-Sayed YY, Caughey AB, Lyell DJ . Neonatal medical admission in a term and late-preterm cohort exposed to magnesium sulfate. Am J Obstet Gynecol 2011; 204 (515): e1–e7.
Greenberg MB, Penn AA, Whitaker KR, Kogut EA, El-Sayed YY, Caughey AB et al. Effect of magnesium sulfate exposure on term neonates. J Perinatol 2013; 33: 188–193.
Landon MB, Hauth JC, Leveno KJ, Spong CY, Leindecker S, Varner MW et al. Maternal and perinatal outcomes associated with a trial of labor after prior cesarean delivery. N Engl J Med 2004; 351: 2581–2589.
Bloom SL, Leveno KJ, Spong CY, Gilbert S, Hauth JC, Landon MB et al. Decision-to-incision times and maternal and infant outcomes. Obstet Gynecol 2006; 108: 6–11.
Riaz M, Porat R, Brodsky NL, Hurt H . The effects of maternal magnesium sulfate treatment on newborns: a prospective controlled study. J Perinatol 1998; 18: 449–454.
Abbassi-Ghanavati M, Alexander JM, McIntire DD, Savani RC, Leveno KJ . Neonatal effects of magnesium sulfate given to the mother. Am J Perinatol 2012; 29: 795–799.
Green KW, Key TC, Coen R, Resnik R . The effects of maternally administered magnesium sulfate on the neonate. Am J Obstet Gynecol 1983; 146: 29–33.
Johnson LH, Mapp DC, Rouse DJ, Spong CY, Mercer BM, Keveno KJ et al. Association of cord blood magnesium concentration and neonatal resuscitation. J Pediatr 2012; 160: 573–577.
Acknowledgements
We acknowledge the assistance of NICHD, the MFMU Network and the Protocol Subcommittee in making the database available on behalf of the project. The contents of this report represent the views of the authors and do not represent the views of the Eunice Kennedy Shriver National Institute of Child Health and Human Development Maternal–Fetal Medicine Units Network or the National Institutes of Health.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Girsen, A., Greenberg, M., El-Sayed, Y. et al. Magnesium sulfate exposure and neonatal intensive care unit admission at term. J Perinatol 35, 181–185 (2015). https://doi.org/10.1038/jp.2014.184
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/jp.2014.184
This article is cited by
-
Neonatal magnesium levels are safe after maternal MgSO4 administration: a comparison between unexposed preterm neonates and neonates exposed for fetal neuroprotection or maternal eclampsia prevention—a cohort study
European Journal of Pediatrics (2022)
-
Neonatal Effects of Maternal Magnesium Sulphate in Late Preterm and Term Pregnancies
The Journal of Obstetrics and Gynecology of India (2019)